The RADIANCE II trial aimed to build on existing data to demonstrate that ultrasound renal denervation can lower blood pressure in patients with uncontrolled hypertension. In this touchCARDIO interview, we speak with Dr Ajay Kirtane (Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY, USA) to discuss the outcomes of the RADIANCE II trial and the clinical implications of these findings.
The abstract entitled ‘Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial’ was presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, 16 – 19, September 2022.
- How did the RADIANCE II trial build on existing knowledge, and what type of patients were included in the study? (0:17)
- What were the key findings from the RADIANCE II trial? (1:19)
- Did you see any notable safety signals or common adverse events in using ultrasound renal denervation for patients with hypertension? (2:20)
- How do you think these trial findings can be incorporated into future routine practice, and contribute to more efficacious management of uncontrolled hypertension? (2:59)
Disclosures: Ajay Kirtane is a consultant for IMDS, has received expenses from Abbott Vascular, Boston Scientific, Chiesi, CSI, Medtronic, OpSens, Philips, ReCor Medical, Regeneron, Siemens and Zoll. Ajay Kirtane reports Institutional funding to Columbia University and/or Cardiovascular Research Foundation from Abbott Vascular, Amgen, Biotronik, Bolt Medical, Boston Scientific, Canon, Chiesi, CSI, Magenta Medical, Medtronic, Merck, Neurotronic, Philips, ReCor Medical, Shockwave Medical and SoniVie. In addition to research grants, institutional funding includes fees paid to Columbia University and/or Cardiovascular Research Foundation for consulting and/or speaking engagements in which he controlled the content.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of TCT 2022
Access more content on Hypertension here
Share this Video
Related Videos In Hypertension
Kelly Chin, ACC 2023: The treatment paradigm for patients with pulmonary arterial hypertension
Recommended therapy for patients with pulmonary arterial hypertension is generally a combination of an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the treatment paradigm. Dr Chin presented an abstract entitled ‘Efficacy And Safety Of […]
Kelly Chin, ACC 2023: A DUE phase III study, a macitentan and tadalafil combination for patients with pulmonary arterial hypertension
The aim of the A DUE study was to assess the combination of macitentan and tadalafil for patients with pulmonary arterial hypertension. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the findings of the trial and the clinical impact. The abstract entitled ‘Efficacy And […]
Marius Hoeper, ACC 2023: STELLAR phase III trial results – Sotatercept for the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease involving proliferative remodeling of the pulmonary vessels and elevations in pulmonary vascular resistance (PVR). Despite recent treatment advances, the associated morbidity and mortality rates of the disease are still high. In this touchCARDIO interview, we speak with Prof. Marius Hoeper (Department of Respiratory Medicine, Hannover Medical School, Hannover, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!